AKT1 and cancer: The phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling pathway is highly active in many cell types, and numerous small molecule inhibitors targeting the PI3K/AKT pathway have been developed for cancer treatment.